{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:30:18Z","timestamp":1761741018563,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2021]]},"DOI":"10.6061\/clinics\/2021\/e2251","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T17:05:22Z","timestamp":1616173522000},"page":"e2251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III\/IV non-small-cell lung cancer: A retrospective study"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8411-9994","authenticated-orcid":false,"given":"Yan","family":"Lan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2795-6865","authenticated-orcid":false,"given":"Shuo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0809-6791","authenticated-orcid":false,"given":"Weihong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9430-0682","authenticated-orcid":false,"given":"Ying","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7146-6735","authenticated-orcid":false,"given":"Xueming","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3666-010X","authenticated-orcid":false,"given":"Fenge","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.6061\/clinics\/2021\/e2251_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-24223-1_1","article-title":"Lung Cancer Statistics","volume":"893","author":"Torre","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.6061\/clinics\/2021\/e2251_bib2","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.6061\/clinics\/2021\/e2251_bib3","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.6061\/clinics\/2021\/e2251_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3810\/hp.2011.10.929","article-title":"Lung cancer screening: a review of available data and current guidelines","volume":"39","author":"Reddy","year":"2011","journal-title":"Hosp Pract (1995)"},{"issue":"3","key":"10.6061\/clinics\/2021\/e2251_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.6061\/clinics\/2021\/e2251_bib6","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"issue":"27","key":"10.6061\/clinics\/2021\/e2251_bib7","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.6061\/clinics\/2021\/e2251_bib8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/annonc\/mdw611","article-title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","volume":"28","author":"Paz-Ares","year":"2017","journal-title":"Ann Oncol"},{"issue":"11","key":"10.6061\/clinics\/2021\/e2251_bib9","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.6061\/clinics\/2021\/e2251_bib10","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.6061\/clinics\/2021\/e2251_bib11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.6061\/clinics\/2021\/e2251_bib12","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.6061\/clinics\/2021\/e2251_bib13","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.6061\/clinics\/2021\/e2251_bib14","article-title":"Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+NSCLC","volume":"33","author":"Shaw","year":"2015","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.6061\/clinics\/2021\/e2251_bib15","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.6061\/clinics\/2021\/e2251_bib16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1586\/17512433.2015.1055252","article-title":"Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"8","author":"Santarpia","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"10.6061\/clinics\/2021\/e2251_bib17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"issue":"15 Suppl","key":"10.6061\/clinics\/2021\/e2251_bib18","article-title":"Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing","volume":"35","author":"Ou","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.6061\/clinics\/2021\/e2251_bib19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.5306\/wjco.v5.i4.560","article-title":"Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation","volume":"5","author":"Becker","year":"2014","journal-title":"World J Clin Oncol"},{"issue":"17","key":"10.6061\/clinics\/2021\/e2251_bib20","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1158\/1078-0432.CCR-07-0560","article-title":"Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus","volume":"13","author":"Riely","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.6061\/clinics\/2021\/e2251_bib21","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-11-1468","article-title":"Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design","volume":"17","author":"Chaft","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.6061\/clinics\/2021\/e2251_bib22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11912-018-0731-9","article-title":"Palliative Care in Lung Cancer: When to Start","volume":"20","author":"Bhattacharya","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"10.6061\/clinics\/2021\/e2251_bib23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/cge.12809","article-title":"Next-generation sequencing of Chinese stage IV lung cancer patients reveals an association between EGFR mutation status and survival outcome","volume":"91","author":"Li","year":"2017","journal-title":"Clin Genet"},{"issue":"2","key":"10.6061\/clinics\/2021\/e2251_bib24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.lungcan.2013.07.014","article-title":"Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study)","volume":"82","author":"Vergnen\u00e0gre","year":"2013","journal-title":"Lung Cancer"},{"issue":"1","key":"10.6061\/clinics\/2021\/e2251_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/jpm.2016.0064","article-title":"The Impact of Hospice Services in the Care of Patients with Advanced Stage Nonsmall Cell Lung Cancer","volume":"20","author":"Duggan","year":"2017","journal-title":"J Palliat Med"},{"issue":"3","key":"10.6061\/clinics\/2021\/e2251_bib26","first-page":"911","article-title":"Palliative care and psychosocial care in metastatic non-small cell lung cancer: factors affecting utilisation of services and impact on patient survival","volume":"27","author":"Duggan","year":"2019","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.6061\/clinics\/2021\/e2251_bib27","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1586\/era.13.47","article-title":"Targeted therapy for non-small-cell lung cancer: past, present and future","volume":"13","author":"Forde","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"10.6061\/clinics\/2021\/e2251_bib28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","article-title":"Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"28","author":"Jackman","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.6061\/clinics\/2021\/e2251_bib29","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","article-title":"Acquired resistance to TKIs in solid tumours: learning from lung cancer","volume":"11","author":"Camidge","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"12 Pt 2","key":"10.6061\/clinics\/2021\/e2251_bib30","doi-asserted-by":"crossref","first-page":"4227s","DOI":"10.1158\/1078-0432.CCR-040007","article-title":"The biology of epidermal growth factor receptor in lung cancer","volume":"10","author":"Scagliotti","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.6061\/clinics\/2021\/e2251_bib31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/bjc.1993.306","article-title":"The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival","volume":"68","author":"Veale","year":"1993","journal-title":"Br J Cancer"},{"issue":"4","key":"10.6061\/clinics\/2021\/e2251_bib32","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/bjc.1998.106","article-title":"Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas","volume":"77","author":"Volm","year":"1998","journal-title":"Br J Cancer"},{"issue":"9","key":"10.6061\/clinics\/2021\/e2251_bib33","doi-asserted-by":"crossref","first-page":"e612","DOI":"10.1038\/bcj.2017.94","article-title":"High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma","volume":"7","author":"Miller","year":"2017","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.6061\/clinics\/2021\/e2251_bib34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neo.2016.01.003","article-title":"Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma","volume":"18","author":"Tiffen","year":"2016","journal-title":"Neoplasia"},{"issue":"1","key":"10.6061\/clinics\/2021\/e2251_bib35","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12916-016-0705-4","article-title":"Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set","volume":"14","author":"Roszik","year":"2016","journal-title":"BMC Med"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222000813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222000813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:52:08Z","timestamp":1761720728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222000813"},"secondary":[{"URL":"https:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1807-59322021000100238&lng=en&nrm=iso","label":"SCIELO"},{"URL":"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7955145\/","label":"PMC"},{"URL":"https:\/\/www.clinicsjournal.com\/article\/association-of-tumor-mutation-burden-and-epidermal-growth-factor-receptor-inhibitor-history-with-survival-in-patients-with-metastatic-stage-iii-iv-non-small-cell-lung-cancer-a-retrospective-study\/","label":"CLINICS"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":35,"alternative-id":["S1807593222000813"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2021\/e2251","relation":{},"ISSN":["1807-5932"],"issn-type":[{"type":"print","value":"1807-5932"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III\/IV non-small-cell lung cancer: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2021\/e2251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}],"article-number":"e2251"}}